Background Myoferlin is a multifunctional protein expressed in various normal and cancer cells, with novel oncogenic roles being newly discovered. Recently, correlations have been found between myoferlin expression and unfavorable prognosis in various carcinomas. This study investigated the prognostic role of myoferlin expression in papillary thyroid carcinoma (PTC), specifically that associated with nodal metastasis.
Methods We collected clinicopathological data and PTC tissues from 116 patients who had been admitted to Gyeongsang National University Hospital in 2010. Immunohistochemical analysis was performed on surgical specimen-derived tissue microarray blocks. Myoferlin expression was graded, and the relationship between expression level and pathological features of tumors based on the American Joint Committee on Cancer staging system was evaluated.
Results Of the 116 patient samples, 100 cases exhibited positive myoferlin expression. Higher grade of myoferlin expression was correlated with lower T category group (p = .010). Presence of lymph node metastasis was determined to be significantly correlated with low-grade myoferlin expression (p = .019), with no significant difference between pN1a and pN1b tumors.
Conclusions Our study revealed an adverse correlation between myoferlin expression and pathological features of PTC, evidence of the potential prognostic role of myoferlin in PTC lymph node metastasis.
Background The immunotherapeutic role of programmed death-ligand 1 (PD-L1) in life expectancy in many cancers has been highlighted. However, data regarding PD-L1 expression in papillary thyroid carcinoma (PTC) are limited. In this study, we describe the PD-L1 and programmed cell death protein 1 (PD-1) expressions in PTC and analyze their correlation with lymph node (LN) metastasis.
Methods Clinicopathological data were obtained from 116 patients with PTC who were treated in Gyeongsang National University Hospital, Jinju, Korea in 2009. Tissue microarray blocks were made using representative paraffin blocks of classical PTCs excluding follicular variants. Two pathologists graded the proportion and intensity of PD-L1 and PD-1 expression in both tumor and inflammatory cells. According to their proportions, positive PTC cells were scored as negative (0%), grade 1 (1%–50%), and grade 2 (51%–100%). Similarly, positive inflammatory cells were graded as negative (0%), grade 1 (1%–10%), and grade 2 (11%–20%). The intensity of each protein expression was simplified as positive or negative.
Results A statistically significant correlation exists between the proportions of PD-1 and PD-L1 expression both in papillary carcinoma (p=.001) and peritumoral lymphoid cells in the thyroid (p<.001). In addition, the proportion of PD-L1 expression in PTC cells was closely related to metastatic LNs (p=.036).
Conclusions PD-L1 is a valuable predictive marker for LN metastasis in PTC. Immunomodulating therapies that inhibit PD-L1 might be an option for patients with LN metastasis.
Citations
Citations to this article as recorded by
Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma Vitor Barreto Santana, Vitória Machado Krüger, Maria Cristina Yunes Abrahão, Pietru Lentz Martins Cantú, Rosicler Luzia Brackmann, Gisele Moroni Pandolfi, Liane Scheffler Marisco, Gabriela Remonatto, Luciana Adolfo Ferreira, Marcia Silveira Graudenz Head and Neck Pathology.2024;[Epub] CrossRef
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies Atish Mohanty, Michelle Afkhami, Amanda Reyes, Rebecca Pharaon, Holly Yin, Haiqing Li, Dana Do, Diana Bell, Arin Nam, Sue Chang, Thomas Gernon, Robert Kang, Arya Amini, Sagus Sampath, Prakash Kulkarni, Raju Pillai, Vicky Villaflor, Ravi Salgia, Ellie Magh Journal for ImmunoTherapy of Cancer.2024; 12(7): e008505. CrossRef
Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples Marco Dell'Aquila, Pietro Tralongo, Alessia Granitto, Maurizio Martini, Sara Capodimonti, Mariangela Curatolo, Vincenzo Fiorentino, Alfredo Pontecorvi, Guido Fadda, Celestino Pio Lombardi, Maco Raffaelli, Liron Pantanowitz, Luigi Maria Larocca, Esther Dia Journal of Clinical Pathology.2023; 76(10): 671. CrossRef
Analysis of anti‐apoptotic PVT1 oncogene and apoptosis‐related proteins (p53, Bcl2, PD‐1, and PD‐L1) expression in thyroid carcinoma Afaf T. Ibrahiem, Amin K. Makhdoom, Khalid S. Alanazi, Abdulaziz M. Alanazi, Abdulaziz M. Mukhlef, Saad H. Elshafey, Eman A. Toraih, Manal S. Fawzy Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma Wenyue Zhao, Lu Liu, Xuehao Li, Shun Xu International Immunopharmacology.2022; 110: 109031. CrossRef
Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas Peter P. Issa, Mahmoud Omar, Yusef Buti, Chad P. Issa, Bert Chabot, Christopher J. Carnabatu, Ruhul Munshi, Mohammad Hussein, Mohamed Aboueisha, Mohamed Shama, Ralph L. Corsetti, Eman Toraih, Emad Kandil Biomedicines.2022; 10(8): 2051. CrossRef
Expression of β-Catenin in Thyroid Neoplasms (Histopathological and Immunohistochemical Study) Mohamed Sherif Ismail, Amr Mousa Abdel Gawad Mousa, Mohammed Faisal Darwish, M. Mostafa Salem, Randa Said Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 1565. CrossRef
Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma Rujia Qin, Chunyan Li, Xuemin Wang, Zhaoming Zhong, Chuanzheng Sun Cancer Cell International.2021;[Epub] CrossRef
PD‐L1 and thyroid cytology: A possible diagnostic and prognostic marker Marco Dell’Aquila, Alessia Granitto, Maurizio Martini, Sara Capodimonti, Alessandra Cocomazzi, Teresa Musarra, Vincenzo Fiorentino, Alfredo Pontecorvi, Celestino Pio Lombardi, Guido Fadda, Liron Pantanowitz, Luigi Maria Larocca, Esther Diana Rossi Cancer Cytopathology.2020; 128(3): 177. CrossRef
Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma Ilaria Girolami, Liron Pantanowitz, Ozgur Mete, Matteo Brunelli, Stefano Marletta, Chiara Colato, Pierpaolo Trimboli, Anna Crescenzi, Massimo Bongiovanni, Mattia Barbareschi, Albino Eccher Endocrine Pathology.2020; 31(3): 291. CrossRef
Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer Andrea Palermo, Andrea Napolitano, Daria Maggi, Anda Mihaela Naciu, Gaia Tabacco, Silvia Manfrini, Anna Crescenzi, Chiara Taffon, Francesco Pantano, Bruno Vincenzi, Guiseppe Tonini, Daniele Santini European Thyroid Journal.2020; 9(3): 157. CrossRef
A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma Xian Wang, Shan Huang, Xiaocan Li, Dongrui Jiang, Hongzhen Yu, Qiang Wu, Chaobing Gao, Zhengsheng Wu, Yi-Hsien Hsieh PLOS ONE.2018; 13(7): e0200290. CrossRef
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis Daniel Lubin, Ezra Baraban, Amanda Lisby, Sahar Jalali-Farahani, Paul Zhang, Virginia Livolsi Endocrine Pathology.2018; 29(4): 317. CrossRef
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation Hoi Yan Ng, Jian Li, Lihua Tao, Alfred King-Yin Lam, Kwok Wah Chan, Josephine Mun Yee Ko, Valen Zhuoyou Yu, Michael Wong, Benjamin Li, Maria Li Lung Translational Oncology.2018; 11(6): 1323. CrossRef
Thymoma is the most common neoplasm of the anterior mediastinum and has malignant potential. Germ cell tumors (GCTs) found in the anterior mediastinum are usually benign, and malignant GCTs, such as seminomas, are rare. Histologically, mediastinal seminoma is indistinguishable from testicular seminoma except for site-associated morphological features such as lymphoid follicular hyperplasia. Therefore, excluding metastasis is very important. Recently, we treated a young adult patient with multiple thymic masses that occurred simultaneously. The patient underwent a thymectomy for the removal of the mediastinal masses, one of which was diagnosed as type B2 invasive thymoma, and two of which were diagnosed as primary mediastinal seminomas with massive follicular hyperplasia. The patient received adjuvant chemotherapy after surgical resection. To our knowledge, this is the first description of a thymoma and a mediastinal seminoma occurring simultaneously in the thymus. We present this case along with a literature review.
Citations
Citations to this article as recorded by
Primary germ cell tumours of the mediastinum: A review with emphasis on diagnostic challenges Alexander Fichtner, Alexander Marx, Philipp Ströbel, Felix Bremmer Histopathology.2024; 84(1): 216. CrossRef
Combined type A thymoma and yolk sac tumour of the mediastinum Dong Sheng, Yu-Chen Han Pathology.2024; 56(6): 927. CrossRef
Combined Thymic Epithelial Neoplasms – a Review Annikka Weissferdt International Journal of Surgical Pathology.2023; 31(6): 917. CrossRef
Primary mediastinal seminoma presenting with paraneoplastic anti-Hu encephalitis: a case report and literature review Chelsey M. Williams, Derek B. Allison, Adam B. Coleman, Roshmita Bardhan, Jordan D. Miller, Zin W. Myint Frontiers in Oncology.2023;[Epub] CrossRef
Primary mediastinal seminoma with florid follicular lymphoid hyperplasia: a case report and review of the literature Charlotte Holmes, Peh Sun Loo, Sion Barnard Diagnostic Pathology.2021;[Epub] CrossRef